Skip to main content
Premium Trial:

Request an Annual Quote

Point-of-Care Coronavirus Test From Credo Diagnostics Biomedical Gets CE Mark

NEW YORK – Credo Diagnostics Biomedical announced on Tuesday it has obtained CE mark for an assay to detect SARS-CoV-2, the virus that causes coronavirus disease COVID-19. The test runs on the firm's point-of-care instrument and is now commercially available on countries accepting the CE designation.

The Credo platform, called VitaPCR, performs real-time PCR to detect pathogens in 20 minutes, with one minute of hands-on time. As previously reported, the system needs minimal training to run and involves no additional equipment.

Winston Wong, chairman of Singapore-based Credo, said that better tools are currently needed at front-line locations, like airports. "Rapid and accurate molecular screening [for the] COVID-19 strain will better help contain the virus and allow early actions to be taken, thus preventing tragedies," Wong said. 

The VitaPCR SARS-CoV-2 Assay is now also pending Emergency Use Authorization from the US Food and Drug Administration and Emergency Use Listing from the World Health Organization, the firm noted in a statement.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.